ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 582,07
-0,66%
Dow Jones
40 211,72
0,53%
DAX
18 502,78
-0,52%
Brent Oil
83,705
-0,75%
Bitcoin
63 186,23
-2,57%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NYSE
  6. Teva Pharmaceutical Industries Ltd (TEVA)

  7. Teva Pharmaceutical Industries Ltd (TEVA) Actualités

TEVA

Teva Pharmaceutical Indu... (TEVA)

Teva Pharmaceutical Industries Ltd
De:
Trier par:
 Showing the most relevant articles for your search:NYSE:TEVA
DateHeureSourceTitreSymboleSociété
16/04/202414h00Business WireTeva’s New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO® (deutetrabenazine) TabletsNYSE:TEVATeva Pharmaceutical Industries Ltd
11/04/202414h30Business WireTeva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in ChinaNYSE:TEVATeva Pharmaceutical Industries Ltd
09/04/202422h30Business WireTeva to Host Conference Call to Discuss First Quarter 2024 Financial Results at 8 a.m. ET on May 8, 2024NYSE:TEVATeva Pharmaceutical Industries Ltd
06/04/202419h00Business WireNew Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension at SIRS 2024NYSE:TEVATeva Pharmaceutical Industries Ltd
04/04/202414h30Business WireTeva and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar CandidateNYSE:TEVATeva Pharmaceutical Industries Ltd
01/04/202414h30Business WireClinical Collaboration Agreement between Teva and Launch Therapeutics to Accelerate Development of Dual-Action Asthma Rescue Inhaler (ICS-SABA/TEV-’248) Respiratory Program; Teva and Abingworth Enter Strategic Development Funding AgreementNYSE:TEVATeva Pharmaceutical Industries Ltd
07/03/202422h27Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:TEVATeva Pharmaceutical Industries Ltd
05/03/202422h43Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNYSE:TEVATeva Pharmaceutical Industries Ltd
26/02/202413h00Business WireTeva and Jiangsu Nhwa Forge Strategic Partnership to Promote Patient Access to AUSTEDO® in ChinaNYSE:TEVATeva Pharmaceutical Industries Ltd
24/02/202402h15GlobeNewswire Inc.Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®NYSE:TEVATeva Pharmaceutical Industries Ltd
24/02/202402h15Business WireAlvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®NYSE:TEVATeva Pharmaceutical Industries Ltd
20/02/202414h30Business WireTeva Presents New Data Supporting Safety, Tolerability and Target Engagement of Anti-TL1A (TEV-‘574) Antibody at the 2024 ECCO Annual MeetingNYSE:TEVATeva Pharmaceutical Industries Ltd
13/02/202415h05IH Market NewsHotter-Than-Expected Inflation Data Likely To Weigh On Wall StreetNYSE:TEVATeva Pharmaceutical Industries Ltd
12/02/202423h03IH Market NewsDow Reaches New Record Closing High But Nasdaq, S&P 500 Give Back GroundNYSE:TEVATeva Pharmaceutical Industries Ltd
12/02/202415h13IH Market NewsTeva Pharmaceutical, Urban Outfitters UpgradedNYSE:TEVATeva Pharmaceutical Industries Ltd
31/01/202413h00Edgar (US Regulatory)Form 8-K - Current reportNYSE:TEVATeva Pharmaceutical Industries Ltd
31/01/202413h00Business WireTeva Reports Growth in Fourth Quarter and Full Year 2023NYSE:TEVATeva Pharmaceutical Industries Ltd
31/01/202412h00Business WireTeva Announces Intention to Divest API Business as Part of Pivot to Growth StrategyNYSE:TEVATeva Pharmaceutical Industries Ltd
02/01/202422h30Business WireTeva to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results and 2024 Financial Guidance at 8 a.m. ET on January 31, 2024NYSE:TEVATeva Pharmaceutical Industries Ltd
02/01/202414h50Dow Jones NewsCorcept Therapeutics Shares Slide Premarket on Loss in Teva Patent SuitNYSE:TEVATeva Pharmaceutical Industries Ltd
28/12/202322h30Business WireTeva to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNYSE:TEVATeva Pharmaceutical Industries Ltd
14/12/202314h30Business WireTeva and Biolojic Design Announce Exclusive License Agreement for the Development of a Therapeutic Antibody for Atopic Dermatitis and AsthmaNYSE:TEVATeva Pharmaceutical Industries Ltd
06/12/202317h19Business WireNeue Post-Hoc-Analyse von Phase-3-Daten zeigt, dass AJOVY® (Fremanezumab) Migräneattacken bei Erwachsenen mit Migräne und komorbider Adipositas reduziertNYSE:TEVATeva Pharmaceutical Industries Ltd
06/12/202315h24Business WireUne nouvelle analyse post hoc des données de phase 3 montre qu’AJOVY® (fremanezumab) réduit les crises de migraine chez les adultes souffrant de migraine et d’obésité comorbideNYSE:TEVATeva Pharmaceutical Industries Ltd
06/12/202308h00Business WireNew Post Hoc Phase 3 Data Analysis Shows AJOVY® (fremanezumab) Reduced Migraine Attacks in Adults with Migraine and Co-morbid ObesityNYSE:TEVATeva Pharmaceutical Industries Ltd
30/11/202315h23Dow Jones NewsTeva Closes Collaboration Deal With Sanofi on IBD TreatmentNYSE:TEVATeva Pharmaceutical Industries Ltd
30/11/202314h30Business WireTeva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease TreatmentNYSE:TEVATeva Pharmaceutical Industries Ltd
20/11/202322h30Business WireTeva to Present at the 6th Annual Evercore ISI HealthCONx ConferenceNYSE:TEVATeva Pharmaceutical Industries Ltd
17/11/202314h30Business WireTeva Announces Approval of a Generic Version of Forteo® (teriparatide injection), in the U.S.NYSE:TEVATeva Pharmaceutical Industries Ltd
13/11/202314h10GlobeNewswire Inc.Royalty Pharma and Teva Collaborate to Further Accelerate Olanzapine Lai ProgramNYSE:TEVATeva Pharmaceutical Industries Ltd
 Showing the most relevant articles for your search:NYSE:TEVA

Dernières Valeurs Consultées

LSE
SPLT
Ishs Platinum �
LSE
UB01
Ubsetf E50gba
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés